Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krebs Biochemicals & Industries has a current ratio of 0.09. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Krebs Biochemicals & Industries has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Krebs Biochemicals & Industries's Current Ratio or its related term are showing as below:
BOM:524518'
s Current Ratio Range Over the Past 10 Years
Min: 0.09 Med: 0.41 Max: 0.56
Current: 0.09
During the past 13 years, Krebs Biochemicals & Industries's highest Current Ratio was 0.56. The lowest was 0.09. And the median was 0.41.
BOM:524518's Current Ratio is ranked worse than 97.49% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.97
vs BOM:524518: 0.09
Krebs Biochemicals & Industries (BOM:524518) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Krebs Biochemicals & Industries Current Ratio Related Terms
Krebs Biochemicals & Industries Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krebs Biochemicals & Industries Current Ratio Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Krebs Biochemicals & Industries's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krebs Biochemicals & Industries Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krebs Biochemicals & Industries's Current Ratio distribution charts can be found below:
* The bar in red indicates where Krebs Biochemicals & Industries's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krebs Biochemicals & Industries (BOM:524518) has a Current Ratio of 0.09 as of Mar. 2026. This is 78% below median its historical median of 0.41. Over the past decade, Krebs Biochemicals & Industries' Current Ratio has ranged from 0.09 to 0.56. According to the industry distribution chart, Krebs Biochemicals & Industries ranks #972 out of 997 companies in the Drug Manufacturers industry, placing it in the top 97.5%.
Is Krebs Biochemicals & Industries' Current Ratio too high?
Krebs Biochemicals & Industries' current Current Ratio of 0.09 is 78% below median its 10-year median of 0.41. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.56. The Drug Manufacturers industry median Current Ratio is 1.97. Krebs Biochemicals & Industries' value of 0.09 is 95.4% below this industry median. Based on the distribution chart, Krebs Biochemicals & Industries ranks #972 out of 997 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Krebs Biochemicals & Industries has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krebs Biochemicals & Industries' Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Krebs Biochemicals & Industries ranks #972 out of 997 companies for Current Ratio. This places Krebs Biochemicals & Industries in the lower half of its industry. The industry median Current Ratio is 1.97. Krebs Biochemicals & Industries' value of 0.09 is 95.4% below this benchmark. Historically, Krebs Biochemicals & Industries' own Current Ratio has ranged from 0.09 to 0.56 over the past decade. While the company's 10-year median is 0.41 vs. the industry median of 1.97, Krebs Biochemicals & Industries has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.97, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krebs Biochemicals & Industries's current Current Ratio of 0.09 is 95.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krebs Biochemicals & Industries's current Current Ratio is 0.09, which is 78% below median its own 10-year median of 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krebs Biochemicals & Industries stock overvalued right now?
Based on GuruFocus' analysis, Krebs Biochemicals & Industries (BOM:524518) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹37.88, compared to a current price of ₹57.25 — trading 51.1% above its estimated fair value. The current Current Ratio is 0.09, which is 78% below median its 10-year median of 0.41 and 95.4% below the Drug Manufacturers industry median of 1.97. Krebs Biochemicals & Industries' overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Krebs Biochemicals & Industries (BOM:524518), the current Current Ratio is 0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krebs Biochemicals & Industries (BOM:524518) Overvalued in 2026?
Based on GuruFocus' analysis, Krebs Biochemicals & Industries stock appears to be overvalued.
The current stock price of ₹57.25 is trading 51.1% above its estimated GF Value™ of ₹37.88.
GuruFocus considers Krebs Biochemicals & Industries to be Significantly Overvalued.
Key valuation signals for BOM:524518:
Current Ratio: 0.09 (78% below median its 10-year median of 0.41)
GF Value™: ₹37.88 vs. price of ₹57.25 (51.1% above fair value)
Industry Position: 95.4% below the Drug Manufacturers median (#972 of 997)
No single metric tells the full story. See the BOM:524518 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krebs Biochemicals & Industries Ltd is a biochemical company in India. It is engaged in the business of manufacture of active pharmaceutical ingredients. It has two manufacturing plants in Andhra Pradesh, India - one in Nellore and one in Vizag both Units are equipped for chemical synthesis, fermentation, and enzymatic technologies providing Krebs with production capacity.
40GF Score
Get the complete analysis for BOM:524518
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524518 has been successfully added to your 
